Physician profile
Thomas Thurlow
NPI 1073153573
$1,061.21
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.39 · 2022: $42.81 · 2023: $86.66 · 2024: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.56 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.22 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.57 | 2023-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $73.90 | 2022-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $41.78 | 2024 | Austedo Xr |
| Lundbeck LLC | $38.27 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $36.24 | 2023-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $34.13 | 2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $32.96 | 2023-2024 | Quviviq |
| Tempus Ai, INC | $26.73 | 2024 | |
| Neos Therapeutics, LP | $19.68 | 2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $18.94 | 2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $18.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Thurlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.